Chief executives from Sutro Biopharma Inc (NASDAQ:STRO) will on Wednesday host a conference call. The company outlines that they will hold discussions in line with its ongoing Phase I dose-escalation study.
Officials set to attend
Some of the officials involved include the Chief Executive Officer Bill Newell, Chief Medical Officer Dr. Arturo Molina, Chief Scientific Officer Dr. Trevor Hallam, and Edward Albini, who is the company’s Chief Financial Officer. These discussions take off effective Wednesday, September 9, 2020. The officials have confirmed their attendance, outlining their commitment to contributing towards discussions revolving around the anti-Folate Receptor alpha (FRα) antibody-drug conjugate (ADC) named STRO-002.
According to medical experts, ovarian cancer is posing as a great challenge among women, and it needs to be handled effectively. Also closely linked to this deadly disease is endometrial cancer. Reports show August 31, 2020, as the data cut-off date. In the meantime, the company continues looking forward to what the experts converging in the meeting will have to say to determine its next course of action.
The xDigital Annual Global Meeting and plans underway
A lot has been going on recently, part of that being the company’s take in pronouncing the xDigital Annual Global Meeting set to be conducted later this year. It is expected that the International Gynecologic Cancer Society (IGCS) will have a lot to say, more so in drawing a clear path forward as to what needs to be done. The actual date of the meeting is August 3, 2020. Sources say that anyone interested in the IGCS poster will obtain it on September 9, 2020.
The contact numbers for those wishing to access the live audio webcast and the conference call have been provided. Those are (201) 389-0894 for the international callers and (877) 407-8974 for the domestic ones.
The World ADC Digital 2020 conference is set to take place in September. There are reports that the above-stipulated officials will be making their presentations there. The proof of concept data in line with the next-generation dual conjugated combination immunostimulatory antibody-drug conjugate (IADC) is going to be presented by Dr. Hallam.